Oh, Baby: FDA Decision Takes Nine Months off Acadia's Wait

Word from the FDA that Acadia Pharmaceuticals Inc. will not need another Phase III trial in order to ask for approval of the oral tablet pimavanserin for Parkinson's disease psychosis (PDP) moved the likely launch date up about nine months, analysts estimated, and made at least some investors more sanguine about the chances for market clearance in Alzheimer's disease psychosis (ADP).